NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals — Investor Presentation (January 2020)

36 slides from NGM Biopharmaceuticals's investor presentation, Jan 13, 2020

  1. Slide 1: NGM Biopharmaceuticals Corporate Overview

    NGM Biopharmaceuticals, Inc. CORPORATE OVERVIEW Novel Biology. Powerful Medicines. Transformative Impact. NASDAQ: NGM Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    This presentation contains forward-looking statements, including, but not limited to, statements regarding potential indications for, and planned development of, product candidates in NGM’s pipeline; the planned timing of initiation, enrollment and results of NGM’s clinical trials, including the ann

  3. Slide 3: Company Highlights

    Company Highlights Experienced team with highly productive R&D engine generating on average ~1 development candidate/year Pipeline of four additional product candidates in cardio-metabolic, oncologic and ophthalmic diseases Strategic collaboration with Merck – up to $75M/yr. R&D support1 and NGM opt

  4. Slide 4: Significant Milestones Achieved in 2019

    Significant Milestones Achieved in 2019 Dry AMD: dry age-related macular degeneration 1 Merck has committed to provide R&D reimbursement of up to $50 million per year; if our R&D expenses exceed $50 million in a given year, Merck can either reimburse up to an additional $25 million for use in fundin

  5. Slide 5: Our Expansive Pipeline

    Development Programs 6 Our Expansive Pipeline PRODUCT CANDIDATE PRODUCT DESCRIPTION (DOSING FREQUENCY) POTENTIAL INDICATIONS STAGE OF DEVELOPMENT WORLDWIDE COMMERCIAL RIGHTS Aldafermin(NGM282) FGF19 Analog (Once Daily) NASH NGM313 (MK-3655) FGFR1c/KLB Agonistic Antibody (Once Monthly) NASH, Type 2 D

  6. Slide 6: Key Targeted Pipeline Milestones for 2020

    Key Targeted Pipeline Milestones for 2020 FGF19: fibroblast growth factor 19; FGFR1c/KLB: fibroblast growth factor receptor 1c/beta-klotho; GDF15: growth differentiation factor 15; GFRAL: glial-cell-derived neurotrophic factor receptor alpha-like PC = Preclinical; FPI: first patient in PRODUCT CANDI

  7. Slide 7: Target Population

    Target Population Fibrosis Stage U.S. Prevalence (Millions) 3.5 6.3 3.4 2.0 1.3 Drivers of Mortality Time to Progression Approximately One Fibrosis Stage Worsening Every 7 Years Improving Fibrosis Leads to Better Outcomes for NASH Patients Sources: Dulai et al, Hepatology 2017, 65(5):1557-1565; Sing

  8. Slide 8: Aldafermin Impacts the Key Drivers of NASH Pathogenesis

    Aldafermin Impacts the Key Drivers of NASH Pathogenesis Liver Fat STEATOSIS Hepatic BALLOONING Immune Response INFLAMMATION FIBROSIS Resulting Impact on Disease Progression in the Liver Insulin Resistance, Toxic Fatty Acids Metabolic Dysregulation ALDAFERMIN (NGM282) Actions on Implicated Disease Dr

  9. Slide 9: Aldafermin Targets Fibrosis Reversal and Cirrhosis Prevention in Advanced NASH

    Unlike Many Other Drugs in Development, Aldafermin Targets Fibrosis Reversal and Cirrhosis Prevention in Advanced NASH Patients NASH Patient Segmentation Liver Transplant/ Liver-related Mortality 6.3M 3.4M 2.0M 1.3M F1 F2 F3 F4 Target Patient Populations Metabolic Drugs (Many) Competitive Landscape

  10. Slide 10: NASH Phase 2 Program Provides Foundation for Late-Stage Development

    COHORT 1 COHORT 2 COHORT 3 COHORT 4 Status Completed (Published, The Lancet 2018) Completed (Presented, EASL 2018) Completed (Presented, AASLD 2018) Ongoing (Anticipated topline data 1Q20) Duration 24 Weeks Aldafermin Dose (# Patients) KEY ENDPOINTS/ Assessment Measures NASH Phase 2 Program Provides

  11. Slide 11: Cohort 4: 24-Week Placebo-Controlled Phase 2 Study

    Cohort 4: A 24-Week, Double-Blind, Placebo-Controlled Multi-Center Ph2 Study of Aldafermin in Patients with Biopsy-Proven NASH D -28 D1 W24 Placebo SC QD Aldafermin 1 mg SC QD MRI-PDFF Biopsy W6 78 subjects randomized 2:1 to aldafermin 1 mg or placebo Key inclusion criteria include: Biopsy confirmed

  12. Slide 12: Summary of Phase 2 Data: Liver Fat Content

    Summary of Phase 2 Data: Liver Fat Content 24-Week Cohort 4 IA Liver Fat Content by MRI-PDFF1 MEASURE/ BIOMARKER 17% (Placebo) and 72% (aldafermin 1 mg) of Subjects Achieved ≥ 30% Relative LFC Reduction at Week 24 1 Relative values are calculated as mean change from baseline Cohort 4 interim analysi

  13. Slide 13: Summary of Phase 2 Data: ALT

    Summary of Phase 2 Data: ALT MEASURE/ BIOMARKER -67% -60% ALT (IU/L) ***P<0.001, **P<0.01, *P<0.05 vs baseline *** *** 0.4% -49% ALT (IU/L) Placebo Aldafermin 1 mg 24-Week Cohort 4 IA ALT (IU/L)1 Previous Cohorts ALT (IU/L)1 *** Aldafermin 1 mg (Cohort 3) Aldafermin 3 mg (Cohort 2) Aldafermin 1 mg (

  14. Slide 14: Cohort 4 Interim Analysis: Decreases in ALT and AST

    Cohort 4 Interim Analysis: Rapid and Sustained Decreases in ALT and AST with Aldafermin ALT (IU/L) AST (IU/L) Change in ALT from Baseline (IU/L) *** *** *** *** *** *** *** *** *** *** *** *** *** *** ***P<0.001 vs. baseline (LS mean) Change in AST from Baseline (IU/L) Cohort 4 interim analysis; Pre

  15. Slide 15: Summary of Phase 2 Data: PRO-C3

    Summary of Phase 2 Data: PRO-C3 MEASURE/ BIOMARKER ***P<0.001, **P<0.01, *P<0.05 vs baseline 6% -25% Pro-C3 (ng/mL) Placebo Aldafermin 1 mg 24-Week Cohort 4 IA PRO-C3 (ng/mL)1 Previous Cohorts PRO-C3 (ng/mL)1 -22% -33% Pro-C3 (ng/mL) * ** *** Aldafermin 1 mg (Cohort 3) Aldafermin 3 mg (Cohort 2) Ald

  16. Slide 16: Cohort 4 Interim Analysis: Reduction in PRO-C3

    Cohort 4 Interim Analysis: Rapid and Sustained Statistically Significant Reduction in PRO-C3 as Early as Week 2 Change in Pro-C3 from Baseline (ng/mL) *** *** *** *** *** *** ** ***P<0.001, **P<0.01 vs. baseline (LS mean) Cohort 4 interim analysis - Preliminary data W2 W4 W6 W12 W24 W18 W8

  17. Slide 17: Cohort 4 Interim Analysis: LDL-C Managed with Statin Therapy

    Cohort 4 Interim Analysis: LDL-C Changes Effectively Managed with Statin Therapy LDL-C (mg/dl) Aldafermin Aldafermin + Rosuvastatin (If Needed, Titration at W2, W4, W8) Cholesterol FGFR4 C4 Bile Acids CYP7A1 Reduce LDL Receptors LDL cholesterol levels return to baseline and/or target of < 100 mg/dl

  18. Slide 18: Cohort 4 Interim Analysis: No Serious Adverse Events

    Cohort 4 Interim Analysis: No Serious Adverse Events or Drug Withdrawals with Aldafermin Treatment MedDRA Preferred Term Placebo (N=13) Aldafermin 1.0 mg (N=25) Diarrhea 1 (7.7%) 7 (28%) Headache 5 (38.5%) 3 (12%) Nausea 4 (30.8%) 3 (12%) Arthralgia 0 (0%) 3 (12%) Diabetes Mellitus 2 (15.4%) 2 (8%)

  19. Slide 19: Robust Reduction to Near Normal Levels Across Key Biomarkers

    Consistent Robust Reduction to Near Normal Levels Across Key Biomarkers of Disease STEATOSIS Liver Fat Content by MRI-PDFF FIBROSIS PRO-C3 INFLAMMATION ALT 41% ─ 67% 1 Relative changes are calculated as mean change from baseline at end of treatment (EOT) Cohorts 1-3 and Cohort 4 interim analysis - P

  20. Slide 20: Rapid Regression of Fibrosis at Week 12

    Rapid Regression of Fibrosis at Week 12 (Cohorts 2 and 3) 1 Preliminary data, Cohorts 2-3 All of the patients experiencing improvements were F2 or worse at baseline Across the two cohorts, four subjects had a two-stage fibrosis improvement Improvements Patient Population Over 80% of patients in 3 mg

  21. Slide 21: Exploratory Endpoints: NASH Histological Parameters Improved at Week 12

    Exploratory Endpoints Achieved (Cohorts 2 and 3): All NASH Histological Parameters Improved at Week 12 Overall NAS2 1Preliminary data, Cohorts 2-3 2NAS: NAFLD Activity Score NAS Histological Response at Week 121,2 (% of Patients; n=19 in 3 mg dose of Cohort 2, n=24 in 1 mg Cohort 3) Mean change at w

  22. Slide 22: Aldafermin Development Plan

    Aldafermin Development Plan PHASE 2 – COHORT 4 PHASE 2b (ALPINE 2/3) PHASE 2b – COMPENSATED CIRRHOTICS (ALPINE 4) PHASE 3 PROGRAM Status Ongoing (Topline histology anticipated 1Q20) Ongoing To Initiate 1Q20 To Initiate Planning with Phase 2 Cohort 4 Data Duration 24 Weeks 24 Weeks 48 Weeks TBD Aldaf

  23. Slide 23: NGM313 (MK-3655) for the Treatment of NASH and Type 2 Diabetes

    NGM313 (MK-3655) for the Treatment of NASH and Type 2 Diabetes Agonistic antibody that selectively activates FGFR1c / KLB to regulate energy metabolism Potential to be once-monthly injectable insulin sensitizer for treatment of NASH and T2D Completed Phase 1 SAD/MAD study in obese, insulin resistant

  24. Slide 24: Significant Reduction in LFC Following Single Dose of NGM313

    Significant Reduction in LFC After 5 Weeks Following Single Dose of NGM313 (MK-3655) Absolute LFC (% LS Mean±SE) Absolute LFC MRI-PDFF ****p<0.0001 **** NGM313 Statistically Significant Improvements In: ALT and AST Triglycerides HDL-C, LDL-C PRO-C3 Phase 1b Study in Obese, Insulin Resistant Subjects

  25. Slide 25: Rapid Reduction in HbA1c Without Hypoglycemia After Single Dose

    Rapid Reduction in HbA1c Without Hypoglycemia After Single Dose of NGM313 (MK-3655) HbA1c Reduction in HbA1c observed in insulin-resistant, non-diabetic patients supports promise of NGM313 to potentially improve glucose control in patients with T2D NGM313, 240 mg (n=17) HbA1c, % (Mean±SE) Pioglitazo

  26. Slide 26: NGM313 Has Potential to Complement Aldafermin

    NGM313 (MK-3655) has Potential to Complement Aldafermin by Targeting NASH Population with T2D NASH Patient Segmentation Liver Transplant/ Liver-related Mortality 6.3M 3.4M 2.0M 1.3M F1 F2 F3 F4 Target Patient Populations Metabolic Drugs (Many) Competitive Landscape Drugs with Metabolic and Anti-fibr

  27. Slide 27: Beyond NASH, an Expansive Pipeline in Other Indications

    Development Programs 6 Beyond NASH, an Expansive Pipeline in Other Indications PRODUCT CANDIDATE PRODUCT DESCRIPTION (DOSING FREQUENCY) POTENTIAL INDICATIONS STAGE OF DEVELOPMENT WORLDWIDE COMMERCIAL RIGHTS Aldafermin(NGM282) FGF19 Analog (Once Daily) NASH NGM313 (MK-3655) FGFR1c/KLB Agonistic Antib

  28. Slide 28: Geographic Atrophy is an Advanced Form of AMD

    Geographic Atrophy (GA) is an Advanced Form of AMD CNV (Wet AMD) GA (Dry AMD) Advanced AMD Intermediate AMD Larger or more numerous drusen, +/- pigmentary changes Early AMD Small or intermediate drusen, +/- pigmentary changes Geographic atrophy (GA) is the dry form of advanced AMD, characterized by

  29. Slide 29: Complement Activation is Associated with Development of Advanced AMD

    Complement Activation is Associated with Development of Advanced AMD Fritsche et al. Nat Genet 2016 Variants in the complement pathway account for the majority of the known genetic risk for AMD CFH C9 C2/CFB C3

  30. Slide 30: NGM621 Targets Complement C3

    NGM621 Targets Complement C3, Blocking All Three Pathways of Complement Activation C2 C4 Classical Pathway Lectin Pathway Alternative Pathway Factor B Factor D Lampalizumab (Roche) C3b C5 C5 convertase NGM621 C3a C5a Inflammation Opsonization / Phagocytosis Cell lysis Membrane Attack Complex (MAC) A

  31. Slide 31: NGM621: A Potent Anti-Complement C3 Antibody

    NGM621: A Potent Anti-Complement C3 Antibody Antibody that has high binding affinity for human C3 (KD < 1 nM) Potent inhibition of both classical and alternative pathways of complement activation (IC50 ~ 5-6 nM) Potential for QM (monthly) or Q2M (EOM) intravitreal dosing Anti-C3 Ab reduces vascular

  32. Slide 32: NGM621 Development Initiated

    NGM621 Development Initiated Phase 1 open-label single dose and multiple dose study in patients with GA Primary objective to evaluate the safety, tolerability and pharmacokinetics of intravitreal injection(s) of single and multiple doses of NGM621 Estimated enrollment of ~24 patients with GA seconda

  33. Slide 33: Our Merck Collaboration: Growth-Accelerating Partnership

    DISCOVERY/ PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL FUNDING SOURCE ($94M UPFRONT + $106M EQUITY INVESTMENT) DEVELOPMENT/ COMMERCIAL CONTROL KEY OPT-IN DECISIONS Our Merck Collaboration: Growth-Accelerating Partnership After Human POC Exclusive WW License ($20M License Payment) After Merck ‘Go

  34. Slide 34: 3Q19 Financial Results

    3Q19 Financial Results1 STATEMENT OF OPERATIONS (In thousands, unaudited) THREE MONTHS ENDED SEP 30, 2019 NINE MONTHS ENDED SEP 30, 2019 RELATED PARTY REVENUE $21,568 $72,461 RESEARCH AND DEVELOPMENT EXPENSES $28,953 $87,299 GENERAL AND ADMINISTRATIVE EXPENSES $5,612 $17,208 TOTAL OPERATING EXPENSES

  35. Slide 35: Multiple Potential Value-Driving Catalysts in 2020

    Multiple Potential Value-Driving Catalysts in 2020 Product Candidate Potential Indications Targeted 2020 Milestones Targeted Timing ALDAFERMIN NASH F2/F3 Phase 2 Cohort 4 biopsy data 1Q20 ALDAFERMIN NASH F4 ALPINE 4 FPI 1Q20 ALDAFERMIN NASH F2/F3 ALPINE 2/3 topline data YE20 NGM313 (MK-3655) NASH F2

  36. Slide 36: Novel Biology. Powerful Medicines. Transformative Impact.

    Novel Biology. Powerful Medicines. Transformative Impact. NASDAQ: NGM

NGM Biopharmaceuticals — Investor Presentation (January 2020) on 6ix